BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1480 related articles for article (PubMed ID: 34792005)

  • 1. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
    Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
    Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
    Al-Hussain SA; Farghaly TA; Zaki MEA; Abdulwahab HG; Al-Qurashi NT; Muhammad ZA
    Bioorg Chem; 2020 Dec; 105():104330. PubMed ID: 33038552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
    El-Metwally SA; Abou-El-Regal MM; Eissa IH; Mehany ABM; Mahdy HA; Elkady H; Elwan A; Elkaeed EB
    Bioorg Chem; 2021 Jul; 112():104947. PubMed ID: 33964580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold.
    Hassan A; Badr M; Abdelhamid D; Hassan HA; Abourehab MAS; Abuo-Rahma GEA
    Bioorg Chem; 2022 Mar; 120():105631. PubMed ID: 35091289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
    Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
    Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
    Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors.
    Ali IH; Abdel-Mohsen HT; Mounier MM; Abo-Elfadl MT; El Kerdawy AM; Ghannam IAY
    Bioorg Chem; 2022 Sep; 126():105883. PubMed ID: 35636123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity.
    Mahmoud HK; Farghaly TA; Abdulwahab HG; Al-Qurashi NT; Shaaban MR
    Eur J Med Chem; 2020 Dec; 208():112752. PubMed ID: 32947227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation.
    Ahmed MF; Santali EY; El-Haggar R
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):307-318. PubMed ID: 33349069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
    Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
    Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
    El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
    Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
    Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking.
    Hassan RA; Hamed MIA; Abdou AM; El-Dash Y
    Bioorg Chem; 2022 Aug; 125():105861. PubMed ID: 35569190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
    Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
    Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New proapoptotic chemotherapeutic agents based on the quinolone-3-carboxamide scaffold acting by VEGFR-2 inhibition.
    El-Fakharany ZS; Nissan YM; Sedky NK; Arafa RK; Abou-Seri SM
    Sci Rep; 2023 Jul; 13(1):11346. PubMed ID: 37443185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, docking study, and antitumor evaluation of benzamides and oxadiazole derivatives of 3-phenoxybenzoic acid as VEGFR-2 inhibitors.
    Heriz MH; Mahmood AAR; Yasin SR; Saleh KM; AlSakhen MF; Kanaan SI; Himsawi N; Saleh AM; Tahtamouni LH
    Drug Dev Res; 2024 May; 85(3):e22186. PubMed ID: 38643351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.